(DRW3) Drägerwerk & Co. KGaA (pref) - Ratings and Ratios
Medical, Safety, Respiratory, Monitoring, Equipment
DRW3 EPS (Earnings per Share)
DRW3 Revenue
Description: DRW3 Drägerwerk & Co. KGaA (pref)
Drägerwerk AG & Co. KGaA is a German-based company operating in the Health Care Equipment sub-industry, as classified by the GICS. The companys stock is listed on XETRA under the ticker symbol DRW3.
To evaluate the investment potential of DRW3, we need to examine its financial health and key performance indicators (KPIs). The companys market capitalization stands at approximately 1.14 billion EUR, indicating a mid-cap status. The price-to-earnings (P/E) ratio is around 12.77, suggesting that the stock might be undervalued relative to its earnings. However, the forward P/E ratio is not available, which could be due to a lack of analyst estimates or inconsistent earnings forecasts.
The return on equity (RoE) of 6.70% indicates that Drägerwerk AG is generating a relatively modest return on shareholders equity. To further assess the companys profitability, we should consider other metrics such as revenue growth, operating margins, and return on assets (RoA). Key economic drivers for the company include demand for healthcare equipment, technological advancements, and global healthcare spending trends.
A thorough analysis of Drägerwerk AGs financial statements would be necessary to identify areas of strength and weakness. Income statement analysis, particularly the yearly Income Tax Expense, can provide insights into the companys tax strategy and its impact on net earnings. A detailed examination of the companys cash flow statements and balance sheet would also be required to assess its liquidity, leverage, and overall financial stability.
DRW3 Stock Overview
| Market Cap in USD | 1,326m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception |
DRW3 Stock Ratings
| Growth Rating | 34.3% |
| Fundamental | 64.2% |
| Dividend Rating | 61.1% |
| Return 12m vs S&P 500 | 26.6% |
| Analyst Rating | - |
DRW3 Dividends
| Dividend Yield 12m | 3.33% |
| Yield on Cost 5y | 3.25% |
| Annual Growth 5y | 36.49% |
| Payout Consistency | 79.4% |
| Payout Ratio | 38.0% |
DRW3 Growth Ratios
| Growth Correlation 3m | -4.6% |
| Growth Correlation 12m | 92.3% |
| Growth Correlation 5y | -23.8% |
| CAGR 5y | 1.30% |
| CAGR/Max DD 5y | 0.02 |
| CAGR/Mean DD 5y | 0.03 |
| Sharpe Ratio 12m | 1.77 |
| Alpha | 35.98 |
| Beta | 0.790 |
| Volatility | 25.01% |
| Current Volume | 16.3k |
| Average Volume 20d | 8.3k |
| Stop Loss | 64.6 (-3%) |
| Signal | -1.73 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (99.9m TTM) > 0 and > 6% of Revenue (6% = 201.6m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.17% (prev 25.12%; Δ -2.96pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 190.6m > Net Income 99.9m (YES >=105%, WARN >=100%) |
| Net Debt (269.5m) to EBITDA (315.7m) ratio: 0.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (18.8m) change vs 12m ago 0.04% (target <= -2.0% for YES) |
| Gross Margin 44.86% (prev 43.62%; Δ 1.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 111.7% (prev 110.9%; Δ 0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.93 (EBITDA TTM 315.7m / Interest Expense TTM 21.3m) >= 6 (WARN >= 3) |
Altman Z'' 4.12
| (A) 0.25 = (Total Current Assets 1.76b - Total Current Liabilities 1.01b) / Total Assets 2.99b |
| (B) 0.39 = Retained Earnings (Balance) 1.17b / Total Assets 2.99b |
| (C) 0.06 = EBIT TTM 169.1m / Avg Total Assets 3.01b |
| (D) 0.80 = Book Value of Equity 1.21b / Total Liabilities 1.52b |
| Total Rating: 4.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.21
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 9.54% = 4.77 |
| 3. FCF Margin 3.64% = 0.91 |
| 4. Debt/Equity 0.25 = 2.47 |
| 5. Debt/Ebitda 1.16 = 1.53 |
| 6. ROIC - WACC -0.24% = -0.30 |
| 7. RoE 6.70% = 0.56 |
| 8. Rev. Trend -0.94% = -0.05 |
| 9. Rev. CAGR 2.71% = 0.34 |
| 10. EPS Trend 19.48% = 0.49 |
| 11. EPS CAGR 35.78% = 2.50 |
What is the price of DRW3 shares?
Over the past week, the price has changed by -0.15%, over one month by -0.75%, over three months by -7.50% and over the past year by +51.83%.
Is Drägerwerk & Co. KGaA (pref) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DRW3 is around 68.71 EUR . This means that DRW3 is currently overvalued and has a potential downside of 3.17%.
Is DRW3 a buy, sell or hold?
What are the forecasts/targets for the DRW3 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76.6 | 15% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 75.6 | 13.5% |
DRW3 Fundamental Data Overview
Market Cap EUR = 1.13b (1.13b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 218.9m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 12.467
P/S = 0.3369
P/B = 0.8478
P/EG = 1.46
Beta = 0.36
Revenue TTM = 3.36b EUR
EBIT TTM = 169.1m EUR
EBITDA TTM = 315.7m EUR
Long Term Debt = 154.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 213.3m EUR (from shortTermDebt, last quarter)
Debt = 367.5m EUR (Calculated: Short Term 213.3m + Long Term 154.2m)
Net Debt = 269.5m EUR (from netDebt column, last quarter)
Enterprise Value = 1.28b EUR (1.13b + Debt 367.5m - CCE 218.9m)
Interest Coverage Ratio = 7.93 (Ebit TTM 169.1m / Interest Expense TTM 21.3m)
FCF Yield = 9.54% (FCF TTM 122.2m / Enterprise Value 1.28b)
FCF Margin = 3.64% (FCF TTM 122.2m / Revenue TTM 3.36b)
Net Margin = 2.97% (Net Income TTM 99.9m / Revenue TTM 3.36b)
Gross Margin = 44.86% ((Revenue TTM 3.36b - Cost of Revenue TTM 1.85b) / Revenue TTM)
Tobins Q-Ratio = 1.06 (Enterprise Value 1.28b / Book Value Of Equity 1.21b)
Interest Expense / Debt = 1.46% (Interest Expense 5.35m / Debt 367.5m)
Taxrate = 28.87% (50.6m / 175.4m)
NOPAT = 120.3m (EBIT 169.1m * (1 - 28.87%))
Current Ratio = 1.74 (Total Current Assets 1.76b / Total Current Liabilities 1.01b)
Debt / Equity = 0.25 (Debt 367.5m / last Quarter total Stockholder Equity 1.46b)
Debt / EBITDA = 1.16 (Net Debt 269.5m / EBITDA 315.7m)
Debt / FCF = 3.01 (Debt 367.5m / FCF TTM 122.2m)
Total Stockholder Equity = 1.49b (last 4 quarters mean)
RoA = 3.34% (Net Income 99.9m, Total Assets 2.99b )
RoE = 6.70% (Net Income TTM 99.9m / Total Stockholder Equity 1.49b)
RoCE = 10.28% (Ebit 169.1m / (Equity 1.49b + L.T.Debt 154.2m))
RoIC = 6.75% (NOPAT 120.3m / Invested Capital 1.78b)
WACC = 7.00% (E(1.13b)/V(1.50b) * Re(8.93%)) + (D(367.5m)/V(1.50b) * Rd(1.46%) * (1-Tc(0.29)))
Shares Correlation 5-Years: -22.40 | Cagr: -3.62%
Discount Rate = 8.93% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 66.55% ; FCFE base≈127.0m ; Y1≈83.4m ; Y5≈38.1m
Fair Price DCF = 75.45 (DCF Value 648.9m / Shares Outstanding 8.60m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -0.94 | Revenue CAGR: 2.71%
Rev Growth-of-Growth: -3.36
EPS Correlation: 19.48 | EPS CAGR: 35.78%
EPS Growth-of-Growth: -139.3